ES2588507T3 - CCR4 como diana terapéutica para cáncer - Google Patents

CCR4 como diana terapéutica para cáncer Download PDF

Info

Publication number
ES2588507T3
ES2588507T3 ES12182790.1T ES12182790T ES2588507T3 ES 2588507 T3 ES2588507 T3 ES 2588507T3 ES 12182790 T ES12182790 T ES 12182790T ES 2588507 T3 ES2588507 T3 ES 2588507T3
Authority
ES
Spain
Prior art keywords
ccr4
cells
cancer
expression
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12182790.1T
Other languages
English (en)
Spanish (es)
Inventor
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Frances Balkwill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2588507(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of ES2588507T3 publication Critical patent/ES2588507T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
ES12182790.1T 2007-09-18 2008-09-18 CCR4 como diana terapéutica para cáncer Active ES2588507T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718167 2007-09-18
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target

Publications (1)

Publication Number Publication Date
ES2588507T3 true ES2588507T3 (es) 2016-11-03

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12182790.1T Active ES2588507T3 (es) 2007-09-18 2008-09-18 CCR4 como diana terapéutica para cáncer
ES12183760.3T Active ES2612690T3 (es) 2007-09-18 2008-09-18 Marcador de cáncer y diana terapéutica
ES08806315.1T Active ES2443541T3 (es) 2007-09-18 2008-09-18 CCR4 como marcador de cáncer

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES12183760.3T Active ES2612690T3 (es) 2007-09-18 2008-09-18 Marcador de cáncer y diana terapéutica
ES08806315.1T Active ES2443541T3 (es) 2007-09-18 2008-09-18 CCR4 como marcador de cáncer

Country Status (11)

Country Link
US (2) US9134293B2 (https=)
EP (3) EP2533047B1 (https=)
JP (2) JP5774309B2 (https=)
AU (1) AU2008300413B2 (https=)
CA (1) CA2699702C (https=)
DK (3) DK2535716T3 (https=)
ES (3) ES2588507T3 (https=)
GB (1) GB0718167D0 (https=)
PL (3) PL2176664T3 (https=)
RU (2) RU2529797C2 (https=)
WO (1) WO2009037454A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
EP2771488B1 (en) 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
BR112014013138B1 (pt) 2011-12-01 2022-06-28 Chemocentryx, Inc Compostos de anilinas substituídas como antagonistas de ccr(4) e composição farmacêutica compreendendo os mesmos
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
EP3065774B1 (en) * 2013-11-06 2021-05-26 Janssen Biotech, Inc. Anti-ccl17 antibodies
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
WO2016050904A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
CN110603056A (zh) * 2017-05-19 2019-12-20 日本全药工业株式会社 基于ccr4阻断的调节性t细胞浸润抑制方法及犬的肿瘤性疾病的治疗方法
KR102817790B1 (ko) 2018-08-29 2025-06-05 케모센트릭스, 인크. C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
US20020132836A1 (en) 2000-10-11 2002-09-19 Chemocentryx Inc. Compounds and methods for modulating CCR4 function
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
SI1326617T1 (sl) 2000-10-18 2007-02-28 Schering Ag Uporaba 11 beta-(4-acetilfenil)-17 beta-hidroksi-17 alfa-(1,1,2,2,2-pentafluoroetil)estra-4,9-dien-3-ona za pripravo zdravila za zdravljenje raka dojk, raka jajcnikov, endometrijskega raka, mieloma in meningioma
CA2439279A1 (en) * 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2003014153A2 (en) 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use.
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
EP1688436A4 (en) * 2003-10-08 2009-12-02 Kyowa Hakko Kirin Co Ltd ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
JPWO2005053741A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK2135949T3 (da) 2006-02-14 2013-02-04 Noxxon Pharma Ag MCP-1-bindende nukleinsyrer
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
US9134293B2 (en) 2015-09-15
PL2176664T3 (pl) 2014-04-30
EP2533047B1 (en) 2016-05-11
US10261099B2 (en) 2019-04-16
CA2699702A1 (en) 2009-03-26
PL2535716T3 (pl) 2017-06-30
RU2529797C2 (ru) 2014-09-27
EP2533047A1 (en) 2012-12-12
JP2010539508A (ja) 2010-12-16
DK2176664T3 (da) 2014-01-20
US20100278844A1 (en) 2010-11-04
WO2009037454A2 (en) 2009-03-26
EP2535716A2 (en) 2012-12-19
GB0718167D0 (en) 2007-10-31
JP2015212703A (ja) 2015-11-26
AU2008300413A1 (en) 2009-03-26
DK2533047T3 (en) 2016-08-22
RU2010123921A (ru) 2011-12-20
EP2176664A2 (en) 2010-04-21
PL2533047T3 (pl) 2016-11-30
EP2535716A3 (en) 2013-03-13
JP5774309B2 (ja) 2015-09-09
EP2535716B1 (en) 2016-11-02
DK2535716T3 (en) 2017-02-13
RU2014128513A (ru) 2016-02-10
WO2009037454A3 (en) 2009-05-07
AU2008300413B2 (en) 2014-09-11
US20160223572A1 (en) 2016-08-04
EP2176664B1 (en) 2013-11-06
JP6234967B2 (ja) 2017-11-22
ES2612690T3 (es) 2017-05-18
CA2699702C (en) 2018-03-06
ES2443541T3 (es) 2014-02-19

Similar Documents

Publication Publication Date Title
ES2588507T3 (es) CCR4 como diana terapéutica para cáncer
Negus et al. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of CC chemokines
Ohta et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients
Nazarian et al. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study
US10161936B2 (en) Method and kit for cytokine analysis from a human whole blood sample
Withers et al. Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma
EP2805166A1 (en) Method for the prognosis of survival time of a patient suffering from a solid cancer
Saied et al. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours
EP1601795A2 (en) Method for determining susceptibility of tumor to treatment with anti-neoplastic agent
Duysinx et al. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions
Wang et al. Overexpression of IGFBP5, but not IGFBP3, correlates with the histologic grade of human diffuse glioma: a tissue microarray and immunohistochemical study
Sekuła et al. Downregulation of the CXCR4 receptor inhibits cervical carcinoma metastatic behavior in vitro and in vivo
Williams et al. Spatial insights into tumor immune evasion illuminated with 1000-plex RNA profiling with CosMx Spatial Molecular Imager
Hsing et al. Tissue microarray analysis of interleukin-20 expression
AU2013203349B2 (en) Cancer marker and therapeutic target
Patai et al. Uterine leiomyosarcoma with osteoclast like giant cells and long standing systemic symptoms
Koelzer et al. Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform
Lin BAFF, GDF-15 and Osteopontin as Biomarkers in the Early-metastasis of Uveal Melanoma
CN101893630A (zh) 一种检测膜联蛋白a3表达水平的方法
Stoika et al. EFFECT OF ANTICANCER DRUGS ON PRODUCTION OF TRANSFORMING GROWTH FACTOR β AND EXPRESSION OF P53 AND BCl-2 PROTEINS BY MCF-7 AND T47D CEll lINES OF HUMAN BREAST CARCINOMA
Albayrak et al. The double immunostaining of CD133 and Ki-67 favours a significant co-localization pattern in fibroblastic subtype of meningiomas
Kim et al. Bone marrow invasion and mylohyoid muscle invasion may indicate cervical lymph node metastasis from oral squamous cell carcinoma of the posterior mandibular alveolar ridge
van Geelen et al. Prognostic significance of TRAIL, DR4 and DR5 expression in adjuvant treated stage III colon cancer patients